Innate Pharma S.A Earning Date (IPHA)

USA |NASDAQ |USD |ADR

IPHA Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Sep 30, 2021 (est) Jun 30, 2021 - $-0.18 $-0.40
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Sep 30, 2021 (est) Jun 30, 2021 - - $18.37M

Innate Pharma S.A's next estimated earnings date (based on same quarter last year's date) is Sep 30, 2021 for the fiscal quarter ending Jun 30, 2021.

IPHA Earnings Date & History Chart

IPHA Earnings & Revenue Forecast

IPHA Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast

IPHA Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend

IPHA Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast

IPHA Earnings Date & Revenue History

IPHA Earnings History

|
Show More
Show More

IPHA Revenue History

|
Show More
Show More

Innate Pharma S.A Next Earnings Date & Report

IPHA Jun 2021 (FQ) Earnings Date & Report Preview

IPHA's next estimated earnings date (based on same quarter last year's report date) is Sep 30, 2021 for the fiscal quarter ending Jun 30, 2021.

Innate Pharma S.A Previous Earnings Dates & Reports

IPHA Previous Earnings Date & Report Recap: Mar 2021 (FQ)

Innate Pharma S.A's previous earnings date was Jun 30, 2021 for its fiscal quarter ended Mar 31, 2021.

IPHA's earnings per share (EPS) was $-0.18.

The EPS was lower than the previous fiscal quarter (Dec 2020) by 1.14%, and lower than the same period a year before (Mar 2020) by 141.85%.

IPHA Previous Earnings Date & Report Recap: Dec 2020 (FY)

Innate Pharma S.A's previous annual earnings date was Mar 31, 2021 for its fiscal year ended Dec 31, 2020.

IPHA's earnings per share (EPS) was $-1.06.

Revenues were $56.83M, down by -17.60% from previous year's revenue.

The company reported a net income of $-63.98M.

Innate Pharma S.A reported a free cash flow of $-63.05M for its fiscal year, compared to $-30.48M a year ago.

The company ended the fiscal year with $19.09M in total debt, an increase of 1.94% compared to the previous year.